Jacobs & Co. CA Purchases 3,256 Shares of Intuitive Surgical, Inc. $ISRG

Jacobs & Co. CA boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 29,299 shares of the medical equipment provider’s stock after acquiring an additional 3,256 shares during the period. Jacobs & Co. CA’s holdings in Intuitive Surgical were worth $11,913,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Valley Wealth Managers Inc. lifted its position in Intuitive Surgical by 2.4% during the third quarter. Valley Wealth Managers Inc. now owns 4,954 shares of the medical equipment provider’s stock worth $2,014,000 after buying an additional 115 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI grew its holdings in Intuitive Surgical by 6.4% in the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 41,642 shares of the medical equipment provider’s stock valued at $16,933,000 after buying an additional 2,512 shares during the period. Atlas Brown Inc. increased its stake in shares of Intuitive Surgical by 6.0% during the 3rd quarter. Atlas Brown Inc. now owns 563 shares of the medical equipment provider’s stock valued at $229,000 after acquiring an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of Intuitive Surgical during the 3rd quarter valued at about $439,000. Finally, GK Wealth Management LLC purchased a new position in shares of Intuitive Surgical during the 3rd quarter worth about $126,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 2.1%

Shares of ISRG stock opened at $423.96 on Friday. The stock has a market cap of $149.78 billion, a price-to-earnings ratio of 48.56, a price-to-earnings-growth ratio of 3.13 and a beta of 1.46. Intuitive Surgical, Inc. has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The firm’s 50 day moving average price is $386.36 and its two-hundred day moving average price is $411.26.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. Intuitive Surgical’s revenue for the quarter was up 18.4% on a year-over-year basis. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 8.87 EPS for the current fiscal year.

Insider Activity

In related news, EVP Gary Loeb sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the executive vice president directly owned 5,320 shares in the company, valued at approximately $2,016,280. This represents a 6.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Ladd sold 72 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total value of $28,303.20. Following the completion of the transaction, the director directly owned 179 shares in the company, valued at $70,364.90. This trade represents a 28.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,370 shares of company stock worth $4,891,989 in the last quarter. Insiders own 0.60% of the company’s stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Barclays upgraded Intuitive Surgical to “strong buy” and initiated coverage at “overweight,” citing the company’s high-quality healthcare-equipment business despite a softer medical-device market. The bullish rating provides a near-term catalyst for the shares. Barclays initiates coverage of Intuitive Surgical
• Positive Sentiment: Piper Sandler also assigned a Buy rating, reinforcing favorable sell-side sentiment around ISRG. Intuitive Surgical gets a Buy from Piper Sandler
• Positive Sentiment: The company’s single-port robotic platform is gaining momentum, with rising procedures, utilization and system placements. Expanding medical indications and international adoption could support longer-term revenue growth. Can ISRG’s Single-Port Platform Become the Next Billion-Dollar Franchise?
• Neutral Sentiment: Analysts’ average recommendation remains bullish, but commentary warns that consensus ratings can be overly optimistic and that ISRG’s valuation leaves limited room for disappointment. Is Intuitive Surgical a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: A reported short-interest figure of zero shares and a zero-day days-to-cover ratio suggests the latest short-interest data may be incomplete or erroneous, limiting its usefulness as a trading signal.
• Negative Sentiment: Jim Cramer expressed concern that Johnson & Johnson and other rivals could intensify competition in robotic surgery, potentially pressuring ISRG’s long-term market position. Intuitive Surgical and JNJ Give Jim Cramer More Than Valuation to Consider

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ISRG shares. Citigroup lowered their target price on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. BNP Paribas Exane upgraded shares of Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. TD Cowen lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. dropped their price objective on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a report on Friday, July 17th. Finally, UBS Group started coverage on Intuitive Surgical in a report on Tuesday, July 28th. They set a “neutral” rating and a $500.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $502.53.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.